Empowered Funds LLC Acquires 31,257 Shares of Humana Inc. $HUM

Key Points

• Empowered Funds LLC significantly increased its stake in Humana Inc. by 814.8% during the first quarter, holding a total of 35,093 shares valued at $9.29 million.
• Humana's stock has recently experienced a 12.4% decline, with its current price at $271.95, following earnings that missed analysts' estimates.
• The company has a dividend of $0.885 per share set to be paid on October 31st, representing a yield of 1.3% based on an annualized payout of $3.54.

Empowered Funds LLC increased its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 814.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,093 shares of the insurance provider's stock after purchasing an additional 31,257 shares during the quarter. Empowered Funds LLC's holdings in Humana were worth $9,286,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Janney Montgomery Scott LLC acquired a new position in shares of Humana during the 1st quarter worth about $1,309,000. Envestnet Asset Management Inc. raised its stake in Humana by 2.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider's stock valued at $33,256,000 after acquiring an additional 2,950 shares during the last quarter. Circle Wealth Management LLC purchased a new position in shares of Humana during the 1st quarter worth approximately $425,000. Rhumbline Advisers raised its stake in shares of Humana by 3.3% during the 1st quarter. Rhumbline Advisers now owns 246,037 shares of the insurance provider's stock worth $65,101,000 after buying an additional 7,909 shares in the last quarter. Finally, Arizona State Retirement System increased its stake in Humana by 3.4% in the 1st quarter. Arizona State Retirement System now owns 35,337 shares of the insurance provider's stock valued at $9,350,000 after purchasing an additional 1,165 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

Shares of NYSE HUM traded down $2.36 during midday trading on Friday, hitting $276.36. 1,138,341 shares of the company's stock were exchanged, compared to its average volume of 1,648,760. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The stock's 50 day moving average price is $265.34 and its 200-day moving average price is $257.18. The firm has a market cap of $33.24 billion, a P/E ratio of 21.21, a PEG ratio of 1.64 and a beta of 0.44. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $325.75.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The firm had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The business's revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter last year, the company earned $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. Equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Friday, September 26th. Humana's payout ratio is 27.17%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on HUM shares. Barclays increased their target price on Humana from $275.00 to $315.00 and gave the company an "equal weight" rating in a report on Friday, September 5th. Wells Fargo & Company decreased their price objective on Humana from $348.00 to $344.00 and set an "overweight" rating on the stock in a report on Thursday, August 14th. Sanford C. Bernstein lifted their target price on Humana from $269.00 to $341.00 and gave the company an "outperform" rating in a report on Friday, September 5th. Truist Financial cut their price objective on Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a research report on Wednesday, July 16th. Finally, Bank of America boosted their price target on Humana from $285.00 to $312.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 2nd. Seven equities research analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $289.24.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.